
|Articles|March 1, 2002
Greater IOP-lowering effect of drug seen in black population
Memphis, TN-Travoprost 0.004% ophthalmic solution (Travatan, Alcon) is an effective IOP-lowering medication in patients of all racial origins. However, travoprost reduces IOP more in black patients compared with non-black patients, and its efficacy in blacks exceeds that associated with both timolol (Timoptic, Merck) and latanoprost (Xalatan, Pharmacia), said Peter A. Netland, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Neurotrophic keratitis outcomes improve with early, stage-based care
5













































.png)


